20-34942488-C-T
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000178.4(GSS):c.491G>A(p.Arg164Gln) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000787 in 1,613,160 control chromosomes in the GnomAD database, with no homozygous occurrence. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000178.4 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
- inherited glutathione synthetase deficiencyInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- glutathione synthetase deficiency with 5-oxoprolinuriaInheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| GSS | NM_000178.4 | c.491G>A | p.Arg164Gln | missense_variant, splice_region_variant | Exon 5 of 13 | ENST00000651619.1 | NP_000169.1 | |
| GSS | NM_001322494.1 | c.491G>A | p.Arg164Gln | missense_variant, splice_region_variant | Exon 5 of 13 | NP_001309423.1 | ||
| GSS | NM_001322495.1 | c.491G>A | p.Arg164Gln | missense_variant, splice_region_variant | Exon 5 of 13 | NP_001309424.1 | 
Ensembl
Frequencies
GnomAD3 genomes  0.0000394  AC: 6AN: 152144Hom.:  0  Cov.: 32 show subpopulations 
GnomAD2 exomes  AF:  0.0000321  AC: 8AN: 249356 AF XY:  0.0000296   show subpopulations 
GnomAD4 exome  AF:  0.0000828  AC: 121AN: 1461016Hom.:  0  Cov.: 32 AF XY:  0.0000798  AC XY: 58AN XY: 726872 show subpopulations 
Age Distribution
GnomAD4 genome  0.0000394  AC: 6AN: 152144Hom.:  0  Cov.: 32 AF XY:  0.0000269  AC XY: 2AN XY: 74324 show subpopulations 
Age Distribution
ClinVar
Submissions by phenotype
Glutathione synthetase deficiency with 5-oxoprolinuria    Pathogenic:3 
- -
Variant summary: GSS c.491G>A (p.Arg164Gln) results in a conservative amino acid change in the encoded protein sequence. Two of three in-silico tools predict a benign effect of the variant on protein function. At least one publication reports experimental evidence that this variant affects mRNA splicing. The variant allele was found at a frequency of 3.2e-05 in 249356 control chromosomes. The variant of interest was observed in multiple affected individuals via publications in a homozygous or compound heterozygous state. GSS activity in these patients were significantly decreased (Shi_1996 and Njalsson_2005). At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity. ClinVar contains an entry for this variant (Variation ID: 8525). Based on the evidence outlined above, the variant was classified as pathogenic. -
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 164 of the GSS protein (p.Arg164Gln). This variant also falls at the last nucleotide of exon 5, which is part of the consensus splice site for this exon. This variant is present in population databases (rs121909307, gnomAD 0.006%). This missense change has been observed in individual(s) with gluthathione synthetase deficiency (PMID: 8896573, 15717202, 25851806, 28822442). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 8525). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change affects GSS function (PMID: 8896573). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Inborn genetic diseases    Pathogenic:1 
The c.491G>A (p.R164Q) alteration is located in exon 5 (coding exon 4) of the GSS gene. This alteration results from a G to A substitution at nucleotide position 491, causing the arginine (R) at amino acid position 164 to be replaced by a glutamine (Q). However, this change occurs in the last base pair of coding exon4, which makes it likely to have some effect on normal mRNA splicing. Based on data from gnomAD, the A allele has an overall frequency of <0.01% (10/280724) total alleles studied. The highest observed frequency was 0.01% (8/127900) of European (non-Finnish) alleles. This variant has been detected as compound heterozygous and homozygous in multiple unrelated individuals with glutathione synthetase deficiency (Shi, 1996; Tokatli, 2007; Li, 2015). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. In addition, as a missense alteration, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. -
not provided    Pathogenic:1 
Published functional studies using complementation assays demonstrate a damaging effect (Shi et al., 1996); Predicted to destroy the natural spice donor site for intron 5 with skipping of exon 5 (Shi et al., 1996); This variant is associated with the following publications: (PMID: 11445798, 28822442, 17479648, 26669244, 15717202, 25851806, 8896573, 25525159) -
Inherited glutathione synthetase deficiency    Pathogenic:1 
The GSS c.491G>A (p.Arg164Gln) variant has been reported in three studies in individuals with 5-oxoprolinuria (a marker for glutathione synthetase deficiency), including two in a homozygous state, three in a compound heterozygous state with either another missense variant or a deletion variant, and in one heterozygote in whom the second variant was not identified (Shi et al. 1996; Tokatli et al. 2007; Li et al. 2015). The c.491G>A (p.Arg164Gln) variant was absent from 25 controls and is reported at a frequency of 0.00003 in the European (non-Finnish) population of the Exome Aggregation Consortium, though this is based on two alleles only in a region of good sequence coverage so the variant is presumed to be rare. Functional studies in individual fibroblasts and erythrocytes demonstrated that the variant resulted in a defect in splicing and enzyme activity of only 5% of normal levels. Expression of p.Arg164Gln variant cDNAs in both yeast and E. coli showed no detectable GSS activity and a failure to complement growth in yeast (Shi et al. 1996; Tokatli et al. 2007). Based on the collective evidence, the p.Arg164Gln variant is classified as pathogenic for glutathione synthetase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at